GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 73 filers reported holding GRITSTONE ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $60,021,000 | +19.1% | 4,667,242 | 0.0% | 4.62% | +14.6% |
| Q3 2021 | $50,406,000 | +435.6% | 4,667,242 | +352.7% | 4.03% | +364.6% |
| Q2 2021 | $9,412,000 | -3.2% | 1,030,878 | 0.0% | 0.87% | +11.3% |
| Q1 2021 | $9,721,000 | +19.7% | 1,030,878 | -50.0% | 0.78% | +24.6% |
| Q4 2020 | $8,123,000 | +48.7% | 2,061,758 | 0.0% | 0.63% | +27.5% |
| Q3 2020 | $5,464,000 | -60.1% | 2,061,758 | 0.0% | 0.49% | -59.2% |
| Q2 2020 | $13,690,000 | +14.1% | 2,061,758 | 0.0% | 1.20% | -11.6% |
| Q1 2020 | $11,999,000 | -35.1% | 2,061,758 | 0.0% | 1.36% | -56.2% |
| Q4 2019 | $18,494,000 | +3.9% | 2,061,758 | 0.0% | 3.10% | -44.3% |
| Q3 2019 | $17,803,000 | -22.5% | 2,061,758 | 0.0% | 5.57% | -5.4% |
| Q2 2019 | $22,968,000 | -16.2% | 2,061,758 | 0.0% | 5.88% | -10.8% |
| Q1 2019 | $27,421,000 | -13.9% | 2,061,758 | 0.0% | 6.60% | -19.7% |
| Q4 2018 | $31,854,000 | +8.5% | 2,061,758 | -0.0% | 8.22% | +52.9% |
| Q3 2018 | $29,359,000 | – | 2,061,762 | – | 5.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
| Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
| Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
| Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
| Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
| Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
| SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
| Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
| Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |